BSD Medical Corporation (BSDM)’s Investor and Analyst Conference Call Transcript

And, finally on page 14, our revenue goals. If you look at, the company’s history there has been a lot of communication around the activities of the company. There have been some significant expectations about the Hypothermea business and Microwave business. The speculation about what that revenue should do. Our goal not that dissimilar to a higher space remarkable win this last month, is to focus on getting first down. To focus on the most basic principles of running a successful business. To ensure that those building blocks equal the revenue guidance provided here. I’ve given a fairly wide range for 2015 based upon looking at our historical(s) and I believe what can be done. The math is very simple to model, if we execute success for the days from the programs we laid out last week for our sales team. Since 2015, we’ve given guidance to 3.5 million to 5 million. This is likely to tighten and Bill and I should provide better, tighter guidance as we learn more about the business and how each program is working.

And, if you look at the business of the overall global market we know that microwave, the economics of our business. If we grow at market and a little better than our share then we should be able to double those revenues once we establish the base line. We have also provided gross margins that are a little wider than what you would typically expect. And that subject it speaks on the program to ensure that we’ve been competitive relative to the landscape out there.

If you turn to 15, what are the key takeaways? I hope that many of you continue to invest in BSD and to be part of our turnaround and to share in the success of that. I hope to attract new investments. When we step back from the recent stock performance, even the revenue performance, and look at the market. It is a large market. It is growing at greater than 20 percent, undisposable. We’ve dominated by our proven technology that literally everyone knows that microwave is replacing. Most importantly, the focus needs to be very simple, the focus to provide good clinical outcome in providing our positions with in-evident based approach to the market place. To continuing to innovate on our current product pipeline as well as look for additional products, endure technologies, that will keep us in front of innovation.